Caffeine, theophylline and bamifylline are similar as competitive inhibitors of 3',5'-cyclic AMP phosphodiesterase in vitro

International Journal of Immunopathology and Pharmacology

Volumn 10, Issue 2, 1997, Pages 153-158

  Spoto, G ^a   Papponetti, M ^a   Barbacane, R C ^a   Repola, D ^a   Conti, P ^a   Berardi, S ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Bamifylline; Caffeine; Cyclic AMP; Inhibitors; Phosphodiastenase; Theophylline

Indexed keywords

BAMIFYLLINE; CAFFEINE; CYCLIC AMP PHOSPHODIESTERASE; ISOENZYME; THEOPHYLLINE;

ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME KINETICS; PRIORITY JOURNAL;

EID: 0030858785     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Beavo J.A. and D.H. Reifsnyder. 1990. Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:150.
2. Michaeli T., T.J. Bloom, T. Martins, K. Loughney, K. Ferguson, M. Riggs, L. Rodgers, J.A. Beavo and M. Wigler. 1993. J. Biol. Chem. 268: 12925.
3. Giembycz M.A. 1992. Could isoenzyme-selective phosphodiesterase inibitors render bronchodilator therapy redundant in the treatment of bronchial asthma. Biochem. Pharmacol. 43:2041.
4. Torphy T.J. and B.J. Undem. 1991. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512.
5. Giembycz M.A. and G. Dent. 1992. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy 22:337.
6. Raeburn D., J.E. Sounes, A. Tomkinson and J.A. Karlsson. 1993. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma. Prog. Drug Res. 40:9.
7. Karlsson J. A., J. Souness, D. Raeburn, M. Palfreyman and M. Ashton. 1993. Anti-inflammatory effects of novel selective cyclic nucleotide phosphodiesterase inhibitors. In T-lymphocyte and Inflammatory Cell Research in Asthma. ed Jolles G., Karlsson J.A., Taylor J. ed. Academic Press London, p. 323
8. Weinberger-Ohana P., D. Goldschmit, L. Mizrachi and J. Orly. 1984. CNPDE inhhibitor, 3-isobutyl-1-methylxanthine, induces cytodifferentiation of follicular granulosa cells cultured in serum-free medium Endocrinology 115:2160.
9. Yamashita M. 1988. Involvment of cAMP in initiating maturation of the britle-star Amphipholis kochii oocytes:induction of oocyte maturation by inhibitors of cyclic nucleotide phosphodiesterase and activators of adenilate cyclase. Dev. Biol. 125:109.
10. Georges P.A., J. Page and G. Duvernay. 1962. Pharmacologie du AC 3810. Theraphie 17:211.
11. Berti F., F. Magni, G. Rossoni, P. Schiantarelli, S. Bongrani and R. Pasangiklian. 1988. New pharmacological data on the bronchospasmiolytic activity of bamifylline. Arzneim. Forsch./Drug Res. 38:40.
12. Berardi S., M. Papponetti, P. Conti and G. Spoto. 1996. Bamifylline similar to theophylline and caffeine is a competitive inhibitor of the cyclic nucleotide phosphodiesterase V. Int. J. Immunophatol. Pharmacol. 9:29.
13. Spoto G., E. Whitehead, A. Ferraro, P.M. Di Terlizzi, C. Turano and F. Riva. 1991. A reverse-phase HPLC method for cAMP phosphodiesterase activity. Anal. Biochem. 196:207.
14. Spoto G., S. Berardi, G. Ajerba and V. De Laurentis. 1995. A reverse-phase HPLC method for cyclic nucleotide phosphodiesterases activity and classification. Adv. Exp. Med. and Biol. 370:815.
15. Weishaar R.E., S.D. Burrows, D.C. Kobilarz, M.M. Quade and D.B. Evans. 1986. Multiple molecular forms of cyclic nucleotide Phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem. Pharmacol. 35:787.
16. Giorgi M., R. Squitti, P. Bonsi, P. Paggi and G. Toschi. 1994. Activities of CNPDEs in the superior cervical ganglion of Rat: characterization, compartimentalization and observation in young and old animals. Neurochem. Int. 25:493.
17. Berti F., F. Magni, S. Rossoni, S. Schiantarelli, S. Bongrani and R. R. Pasargiklian. 1988. New pharmacological data on the bronchospasmolytic activity of bamifylline. Arzneim Forsch/Drug Res. 38:40.
18. Ashton M.J., D.C. Cook, G. Fenton, J.A. Karlsson, M.N. Palfreyman, D. Raeburn, A.J. Ratcliffe, J.E. Souness, S. Thrairaitnam, N. Vicker. 1994. Selective type IV phosphodiesterase inhibitors as anti-asthmatic agents. The synthesis and biological activities of 3-cyclopenthyloxy-4-methoxybenzamides and analogues. J. Med. Chem. 37:1696.
19. Souness J.E., S.E. Webber, K. Pollock, M.N. PalFreyman, M.J. Ashton, D. Raeburn and J.A. Karlsson. 1994. Comparison of inhibitory actions of RP 73401 and rolipram on cAMP PDE IV from guinea-pig eosinophils and pig aorta. FASEB J. 8:A371.
20. Tomkinson A., J.A. Karlsson and D. Raeburn. 1993. Comparison of the effects of selective inhibitors of PDE type III and IV in airway smooth muscle with differing b-adrenoceptor subtypes. Br. J. Pharmacol. 108:57.
21. Karlsson J.A. and C.G.A. Persson. 1981. Influence of tracheal contraction on relaxant effects in vitro of theophylline and isoprenaline. Er. J. Pharmacol. 74:73.
22. de Boer J., A.J. Philpott, R.G.M. van Amsterdam, M. Shahid, J. Zaagsma and D. Nicholson. 1992.Human bronchial en PDE isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 106:1028.
23. Qian Y., E. Naline, J.A. Karlsson, D. Raeburn and C. Advenier. 1993. Effects of rolipram and siguazodan on the human isolated bronchus and their interaction with isoprenaline and sodium nitroprusside. Br. J. Pharmacol. 109:774.